在2型糖尿病中,狭窄范围的时间和1,5-基醇的相关性在2型糖尿病中
Hang Su1,2, Jiaying Ni2, Danfeng Peng2
1Department of Gerontology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Diabetes, obesity & metabolism
|June 9, 2025
概括
在2型糖尿病患者中,血清1,5-基醇 (1,5-AG) 与狭窄范围 (TITR) 的时间正相关. 1,5-AG水平为8.0μg/ml可能有助于识别TITR超过50%的患者.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 糖尿病管理 糖尿病管理
背景情况:
- 持续血糖监测 (CGM) 为糖尿病管理提供了新的指标.
- 狭窄范围内的时间 (TITR) 是一种新兴的血糖控制指标,反映了在狭窄的目标范围内的葡萄糖变化.
研究的目的:
- 在2型糖尿病患者中研究血清1,5-二醇 (1,5-AG) 和TITR之间的关系.
- 为了确定血清1,5-AG是否可以预测达到特定的TITR值.
主要方法:
- 一项1531名2型糖尿病患者的横截面研究.
- 使用CGM来测量TITR和距离时间 (TIR).
- 使用斯皮尔曼相关性和接收器操作特征 (ROC) 曲线分析来评估血清1,5-AG和TITR之间的关联.
主要成果:
- 血清1,5-AG与TITR显著正相关 (p < 0.001).
- 血清1,5-AG切断值为8.0μg/mL被确定为预测TITR>50% (AUC = 0.693) 的最佳值.
- 将1,5-AG与禁食或食后葡萄糖相结合,提高了预测准确度.
结论:
- 血清1,5-AG是2型糖尿病中TITR的显著相关物.
- 血清1,5-AG水平为8.0μg/mL是识别TITR>50%的患者的潜在生物标志物.
- 1,5-AG提供了一种有价值的非CGM指标,用于在狭窄范围内评估血糖控制.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
715
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
715
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274


